BACKGROUND: European Urological Association guidelines recommend potentially curative inguinal lymphadenectomy for certain cases of penile cancer such as grade 3 and pT2-4 lesions, among others. Anecdotally, the authors have noticed that few patients undergo inguinal lymphadenectomy. Therefore, they assessed the frequency of inguinal lymphadenectomy and the impact of dissection extent on survival using the Surveillance, Epidemiology, and End Results (SEER) database. METHODS: The authors queried 17 SEER registries from 1988 through 2005 for grade 3 and pT2-4 penile cancer patients without distant metastases. Univariate and multivariate analyses examined predictors of inguinal lymphadenectomy. Kaplan-Meier and Cox regression analyses assessed overall 5-year survival across patient- and disease-related characteristics for patients receiving inguinal lymphadenectomy involving <8 or > or = 8 lymph nodes, the latter a surrogate for extent of dissection based on other malignancies. RESULTS: Of 593 patients enrolled, only 26.5% received inguinal lymphadenectomy. In addition to grade 3 (P = .031) and pT2-4 disease (P = .004), age <65 years (P < .001) and marital status (P = .002) were significantly associated with receiving lymph node dissection. Increased overall 5-year survival (hazard ratio, 0.54; 95% confidence interval, 0.36-0.79) was observed in patients of all ages who received lymphadenectomy involving > or = 8 lymph nodes. CONCLUSIONS: A significant number of penile cancer patients at risk for metastases have not received potentially curative inguinal lymphadenectomy. Patients receiving inguinal lymphadenectomy involving > or = 8 lymph nodes experienced improved overall 5-year survival. Guidelines should not only be given more emphasis, but possibly be updated to reflect the benefit of extensive lymph node dissection in high-risk penile cancer patients.
BACKGROUND: European Urological Association guidelines recommend potentially curative inguinal lymphadenectomy for certain cases of penile cancer such as grade 3 and pT2-4 lesions, among others. Anecdotally, the authors have noticed that few patients undergo inguinal lymphadenectomy. Therefore, they assessed the frequency of inguinal lymphadenectomy and the impact of dissection extent on survival using the Surveillance, Epidemiology, and End Results (SEER) database. METHODS: The authors queried 17 SEER registries from 1988 through 2005 for grade 3 and pT2-4 penile cancerpatients without distant metastases. Univariate and multivariate analyses examined predictors of inguinal lymphadenectomy. Kaplan-Meier and Cox regression analyses assessed overall 5-year survival across patient- and disease-related characteristics for patients receiving inguinal lymphadenectomy involving <8 or > or = 8 lymph nodes, the latter a surrogate for extent of dissection based on other malignancies. RESULTS: Of 593 patients enrolled, only 26.5% received inguinal lymphadenectomy. In addition to grade 3 (P = .031) and pT2-4 disease (P = .004), age <65 years (P < .001) and marital status (P = .002) were significantly associated with receiving lymph node dissection. Increased overall 5-year survival (hazard ratio, 0.54; 95% confidence interval, 0.36-0.79) was observed in patients of all ages who received lymphadenectomy involving > or = 8 lymph nodes. CONCLUSIONS: A significant number of penile cancerpatients at risk for metastases have not received potentially curative inguinal lymphadenectomy. Patients receiving inguinal lymphadenectomy involving > or = 8 lymph nodes experienced improved overall 5-year survival. Guidelines should not only be given more emphasis, but possibly be updated to reflect the benefit of extensive lymph node dissection in high-risk penile cancerpatients.
Authors: Suzanne Richter; J Dean Ruether; Lori Wood; Christina Canil; Patricia Moretto; Peter Venner; Joel Gingerich; Urban Emmenegger; Andrea Eisen; Pawel Zalewski; Anthony Joshua; Som Dave Mukherjee; Daniel Heng; Piotr Czaykowski; Denis Soulieres; Norman Blais; Ricardo Rendon; Neil Fleshner; Juanita M Crook; Srikala S Sridhar Journal: Can Urol Assoc J Date: 2013 Nov-Dec Impact factor: 1.862
Authors: James J Jaber; Chad A Zender; Vikas Mehta; Kara Davis; Robert L Ferris; Pierre Lavertu; Rod Rezaee; Paul J Feustel; Jonas T Johnson Journal: Head Neck Date: 2014-01-13 Impact factor: 3.147